FlandersBio on Twitter

Follow us on Twitter

Archive for August 2014 - News

Archive for August 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

AANKOMST EERSTE STUDENTEN VOOR DE INTERNATIONALE UNIVERSITAIRE OPLEIDINGEN IN HET ST.-PIETERSSTATION, GENT

29.08.2014

Topstudenten uit ontwikkelingslanden worden nog voor de start van het academiejaar onthaald door het International Training Centre van de UGent met een intensieve zomercursus die hen voorbereid op integratie in de Vlaamse samenleving en een vliegende academische start. Voor de eerste keer worden zij persoonlijk opgewacht in het St.-Pietersstation. read more

ThromboGenics Business Update H1 2014

29.08.2014

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issues a business and financial update for the six months ending 30 June, 2014. read more

ALS Ice Bucket challenge - FlandersBio

28.08.2014

We would like to thank Jo Bury and Johan Cardoen from VIB for nominating FlandersBio for the ALS Ice Bucket Challenge. With pleasure Henk Joos joins this initiative. ALS is indeed a devastating disease and as a life sciences network organisation we are fully committed to help in the combat of this important disease. read more

ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2014

28.08.2014

Ablynx [Euronext Brussels: ABLX] today announced its results for the six-month period ending 30 June 2014, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adopted by the European Union. The Company's operational highlights are also reported. read more

arGEN-X - Business Update and First Half 2014 Results

27.08.2014

arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provides a business update and announces its financial results for the first half of 2014 (six-month period ended 30 June 2014). read more

TiGenix Business and Financial Update for the First Half of 2014

26.08.2014

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year today. read more

Cardio3 BioSciences meldt financiële resultaten en bedrijfsupdate voor 1ste halfjaar van 2014

25.08.2014

Cardio3 BioSciences NV (C3BS) (NYSE Euronext Brussel en Parijs: CARD), een leider in de ontdekking en ontwikkeling van regeneratieve, beschermende en herstellende therapieën voor de behandeling van hartziekten, kondigt vandaag een bedrijfsupdate en zijn geconsolideerde financiële resultaten aan voor de periode van zes maanden tot 30 juni 2014, opgesteld in overeenstemming met IFRS zoals toegepast in de Europese Unie. read more

MDxHealth Reports First Half Year 2014 Results

22.08.2014

MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014. read more

ABLYNX WILL ANNOUNCE ITS HALF-YEAR RESULTS FOR 2014 WITH WEBCAST

22.08.2014

Ablynx [Euronext Brussels: ABLX] will announce its half-year results for 2014 on Thursday 28 August 2014 at 7.00 am CET. read more

arGEN-X Results for the First Half 2014 and Business Update

22.08.2014

arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, will release its maiden results for the first half 2014 and a business update on Wednesday 27 August 2014. The full report will be available on arGEN-X' website www.argen-x.com in the Investors section from 7am CET. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print